Shine-On BioMedical Co (ROCO:6926) EBITDA Margin %: -214.94% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6926 Shine-On BioMedical Co Ltd ROCO:6926
12 GF Score
Price NT$64.80
! 1 Warning Sign
View Full Analysis

What is Shine-On BioMedical Co EBITDA Margin %?

Shine-On BioMedical Co ROCO:6926 12 EBITDA Margin % is -214.94% as of Dec. 2025. GuruFocus rates ROCO:6926 with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, Shine-On BioMedical Co ranks worse than 68.37% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Shine-On BioMedical Co's EBITDA for the six months ended in Dec. 2025 was NT$-64.48 Mil. Shine-On BioMedical Co's Revenue for the six months ended in Dec. 2025 was NT$30.00 Mil. Therefore, Shine-On BioMedical Co's EBITDA margin for the quarter that ended in Dec. 2025 was -214.94%.

Shine-On BioMedical Co  (ROCO:6926) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Shine-On BioMedical Co EBITDA Margin % Related Terms

Shine-On BioMedical Co EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Shine-On BioMedical Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shine-On BioMedical Co EBITDA Margin % Chart

Shine-On BioMedical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 -346.56 0.00 -361.08

Shine-On BioMedical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -235.42 0.00 0.00 0.00 -214.94

ROCO:6926 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Shine-On BioMedical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shine-On BioMedical Co EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shine-On BioMedical Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Shine-On BioMedical Co's EBITDA Margin % falls into.


ROCO:6926
12GF Score
Shine-On BioMedical Co Ltd ROCO:6926
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shine-On BioMedical Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Shine-On BioMedical Co's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-108.325/30
=-361.08 %

Shine-On BioMedical Co's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-64.483/30
=-214.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -214.94% mean?
Shine-On BioMedical Co (ROCO:6926) has a EBITDA Margin % of -214.94% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shine-On BioMedical Co and its competitors. According to the industry distribution chart, Shine-On BioMedical Co ranks #642 out of 939 companies in the Biotechnology industry, placing it in the top 68.4%.
Is Shine-On BioMedical Co's EBITDA Margin % too high?
Shine-On BioMedical Co's current EBITDA Margin % is -214.94%. Based on the distribution chart, Shine-On BioMedical Co ranks #642 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shine-On BioMedical Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Shine-On BioMedical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shine-On BioMedical Co ranks #642 out of 939 companies for EBITDA Margin %. This places Shine-On BioMedical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shine-On BioMedical Co and its competitors. Shine-On BioMedical Co's current EBITDA Margin % is -214.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shine-On BioMedical Co stock overvalued right now?
Shine-On BioMedical Co (ROCO:6926) has a current EBITDA Margin % of -214.94%. The current EBITDA Margin % is -214.94%. Shine-On BioMedical Co's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shine-On BioMedical Co (ROCO:6926), the current EBITDA Margin % is -214.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shine-On BioMedical Co Business Description

Address No. 573, Taiwan Boulevard, 10th Floor, Section 2, West District, Taichung, TWN
Shine-On BioMedical Co Ltd develops drugs based on antibodies and nucleic acids. The Company researches, develops, manufactures, and distributes antibody anticancer drugs, nucleic acid anticancer drugs. The company's drug development and nucleic acid therapeutics are focused on providing patients with effective cancer treatment options.
12GF Score

Get the complete analysis for ROCO:6926

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$64.80
Price